

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status **Final**

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE**XRAY-CHEST**

»» BOTH THE LUNG FIELDS ARE CLEAR
 »» BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
 »» BOTH THE HILA ARE NORMAL
 »» CARDIAC AND AORTIC SHADOWS APPEAR NORMAL
 »» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL
 »» VISUALIZED BONY THORAX IS NORMAL
 IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO

IMPRESSION :-

NORMAL 2D ECHO STUDY

LVEF 65%

ECG

ECG

ELECTROCARDIOGRAM :-

SINUS RHYTHM.

T-ABNOR5MAQLOITY IN INFERIOR LEASD.

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

C/O FEVER, COLD AND COUGH, WEAKNES WITH SOB

RELEVANT PAST HISTORY

CHEST B/L RONCHI
H/O LSCS 2005 AND 2010

RELEVANT PERSONAL HISTORY

HYPOTHYROID
NOT SIGNIFICANT

RELEVANT FAMILY HISTORY

FATHER :- CAD - PTCA.

OCCUPATIONAL HISTORY

MOTHER :- HYPOTHYROID AND BRONCHIAL ASTHMA
NOT SIGNIFICANT

HISTORY OF MEDICATIONS

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS

1.65

mts

WEIGHT IN KGS.

64

Kgs



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 1 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BMI	24	BMI & Weight Status as follows Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
-----	----	--

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	ASYMMETRICAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
CAROTID PULSATION	NORMAL
TEMPERATURE	AFEBRILE

CARDIOVASCULAR SYSTEM

PERICARDIUM	NORMAL
APEX BEAT	NORMAL
HEART SOUNDS	S1, S2 HEARD NORMALLY
MURMURS	ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST	NORMAL
MOVEMENTS OF CHEST	SYMMETRICAL
BREATH SOUNDS INTENSITY	NORMAL
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)
ADDED SOUNDS	ABSENT

PER ABDOMEN

APPEARANCE	NORMAL
VENOUS PROMINENCE	ABSENT



Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA**REF. DOCTOR : DR. BANK OF BARODA****CODE/NAME & ADDRESS : C000138355**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE
HERNIA	ABSENT
CENTRAL NERVOUS SYSTEM	
HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL
MUSCULOSKELETAL SYSTEM	
SPINE	NORMAL
JOINTS	NORMAL
BASIC EYE EXAMINATION	
CONJUNCTIVA	PALLOR
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	6/6 WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES	6/6 WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES	N6 WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES	N6 WITHIN NORMAL LIMIT
COLOUR VISION	NORMAL
BASIC ENT EXAMINATION	
EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	CLEAR
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED
BASIC DENTAL EXAMINATION	



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 3 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008

**Patient Ref. No. 775000002914684**

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHINEW DELHI 110030
8800465156ACCESSION NO : **0290WD003532**

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

TEETH

REINFECTION RCT SUGGESTS

GUMS

HYPERTYROPHIED

SUMMARY

RELEVANT HISTORY

NOT SIGNIFICANT

RELEVANT GP EXAMINATION FINDINGS

NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS

WITHIN NORMAL LIMITS

RELEVANT NON PATHOLOGY DIAGNOSTICS

NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS

NONE

FITNESS STATUS

FITNESS STATUS

FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

Comments

CLINICAL FINDINGS:-

LOW HB

DYSLIPIDEMIA.

FITNESS STATUS :-

FITNESS STATUS : FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

ADVICE :- LOW FAT WITH HIGH FIBER DIET AND REGULAR PHYSICAL EXERCISE FOR DYSLIPIDEMIA.

ADD TAKE FOOD STUFFS RICH IN IRON i.e. BEATROOT & SPINACH WITH IRON SUPPLEMENTS IN DIET. (NEEDS PHYSICIAN CONSULTATION IF HB < 8 gms%.)

NEED PHYSICIAN CONSULTATION FOR LIFE STYLE MODIFICATION.



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 4 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA		REF. DOCTOR : DR. BANK OF BARODA	
CODE/NAME & ADDRESS : C000138355		ACCESSION NO : 0290WD003532	AGE/SEX : 41 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		PATIENT ID : RITUF041081290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST		CLIENT PATIENT ID:	RECEIVED : 15/04/2023 08:41:25
DELHI		ABHA NO :	REPORTED : 17/04/2023 16:36:44
NEW DELHI 110030			
8800465156			

Test Report Status	Final	Results	Units
--------------------	-------	---------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

Interpretation(s)

MEDICAL HISTORY..... THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

- Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:
- Fit (As per requested panel of tests) - SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician's consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.
- Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.
- Unfit (As per requested panel of tests) - An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.



Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB) METHOD : SPECTROPHOTOMETRY	10.6 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	3.99	3.8 - 4.8	mil/ μ L
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	3.40 Low	4.0 - 10.0	thou/ μ L
PLATELET COUNT METHOD : ELECTRICAL IMPEDANCE	211	150 - 410	thou/ μ L

RBC AND PLATELET INDICES

HEMATOCRIT (PCV) METHOD : CALCULATED	33.5 Low	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED	84.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	26.6 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	31.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED	12.2	11.6 - 14.0	%
MENTZER INDEX	21.1		
MEAN PLATELET VOLUME (MPV) METHOD : CALCULATED	9.4	6.8 - 10.9	fL

WBC DIFFERENTIAL COUNT

NEUTROPHILS METHOD : IMPEDANCE / MICROSCOPY	56	40 - 80	%
LYMPHOCYTES METHOD : IMPEDANCE / MICROSCOPY	40	20 - 40	%
MONOCYTES METHOD : IMPEDANCE / MICROSCOPY	03	2 - 10	%
EOSINOPHILS METHOD : IMPEDANCE / MICROSCOPY	01	1 - 6	%



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 6 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
BASOPHILS		00	0 - 2	%
METHOD : IMPEDANCE / MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT		1.90 Low	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED				
ABSOLUTE LYMPHOCYTE COUNT		1.36	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED				
ABSOLUTE MONOCYTE COUNT		0.10 Low	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED				
ABSOLUTE EOSINOPHIL COUNT		0.03	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED				

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD

E.S.R **40 High** 0 - 20 mm at 1 hr

METHOD : MODIFIED WESTERGREN

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic. It is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 8 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : **0290WD003532**

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 9 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.7	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HPLC TECHNOLOGY

ESTIMATED AVERAGE GLUCOSE(EAG)	116.9 High	< 116.0	mg/dL
--------------------------------	-------------------	---------	-------

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	93	74 - 99	mg/dL
---------------------------	----	---------	-------

METHOD : HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	104	Normal: < 140, Impaired Glucose Tolerance:140-199 Diabetic > or = 200	mg/dL
---------------------------------	-----	--	-------

METHOD : HEXOKINASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL	181	Desirable: <200 BorderlineHigh : 200-239 High : > or = 240	mg/dL
--------------------	-----	--	-------

METHOD : OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES	364 High	Desirable: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High : > or = 500	mg/dL
---------------	-----------------	---	-------

METHOD : ENZYMATIC ASSAY

HDL CHOLESTEROL	36 Low	< 40 Low > or = 60 High	mg/dL
-----------------	---------------	----------------------------	-------

METHOD : DIRECT- NON IMMUNOLOGICAL



Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
CHOLESTEROL LDL		72	Adult levels: Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL
NON HDL CHOLESTEROL		145 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED				
VERY LOW DENSITY LIPOPROTEIN		72.8 High	< or = 30	mg/dL
METHOD : CALCULATED				
CHOL/HDL RATIO		5.0 High	3.3 - 4.4	
LDL/HDL RATIO		2	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3) HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5) Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.25	0.0 - 1.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.12	0.0 - 0.2	mg/dL
METHOD : DIAZOTIZATION			
BILIRUBIN, INDIRECT	0.13	0.00 - 1.00	mg/dL



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 12 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : CALCULATED				
TOTAL PROTEIN		7.4	6.4 - 8.3	g/dL
METHOD : BIURET				
ALBUMIN		4.3	3.50 - 5.20	g/dL
METHOD : BROMOCRESOL GREEN				
GLOBULIN		3.1	2.0 - 4.1	g/dL
METHOD : CALCULATED				
ALBUMIN/GLOBULIN RATIO		1.4	1.0 - 2.0	RATIO
METHOD : CALCULATED				
ASPARTATE AMINOTRANSFERASE(AST/SGOT)		13	UPTO 32	U/L
METHOD : UV WITH P5P				
ALANINE AMINOTRANSFERASE (ALT/SGPT)		14	UPTO 34	U/L
METHOD : UV WITH P5P				
ALKALINE PHOSPHATASE		86	35 - 104	U/L
METHOD : PNPP				
GAMMA GLUTAMYL TRANSFERASE (GGT)		15	5 - 36	U/L
METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE				
LACTATE DEHYDROGENASE		153	135 - 214	U/L
METHOD : ENZYMATIC LACTATE - PYRUVATE(IFCC)				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN		7	6 - 20	mg/dL
METHOD : UREASE KINETIC				
CREATININE, SERUM				
CREATININE		0.71	0.50 - 0.90	mg/dL
METHOD : ALKALINE PICRATE KINETIC JAFFES				
BUN/CREAT RATIO				
BUN/CREAT RATIO		9.86	5.0 - 15.0	
METHOD : CALCULATED				
URIC ACID, SERUM				
URIC ACID		4.3	2.6 - 6.0	mg/dL
METHOD : URICASE/CATALASE UV				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN		7.4	6.4 - 8.3	g/dL
METHOD : BIURET				
ALBUMIN, SERUM				

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

ALBUMIN 4.3 3.5 - 5.2 g/dL
METHOD : BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 3.1 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM 140.5 136.0 - 146.0 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE

POTASSIUM, SERUM 4.11 3.50 - 5.10 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE

CHLORIDE, SERUM 105.3 98.0 - 106.0 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-Used For:

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA		REF. DOCTOR : DR. BANK OF BARODA	
CODE/NAME & ADDRESS : C000138355		ACCESSION NO : 0290WD003532	AGE/SEX : 41 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		PATIENT ID : RITUF041081290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST		CLIENT PATIENT ID :	RECEIVED : 15/04/2023 08:41:25
DELHI		ABHA NO :	REPORTED : 17/04/2023 16:36:44
NEW DELHI 110030			
8800465156			

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

- Diagnosing diabetes.
- Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.
- eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
- eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

- Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
- Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- Interference of hemoglobinopathies in HbA1c estimation is seen in

- Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)



Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 77500002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low**

blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA		REF. DOCTOR : DR. BANK OF BARODA	
CODE/NAME & ADDRESS : C000138355		ACCESSION NO : 0290WD003532	AGE/SEX : 41 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		PATIENT ID : RITUF041081290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST		CLIENT PATIENT ID:	RECEIVED : 15/04/2023 08:41:25
DELHI		ABHA NO :	REPORTED : 17/04/2023 16:36:44
NEW DELHI 110030			
8800465156			

Test Report Status	Final	Results	Biological Reference Interval	Units
---------------------------	--------------	----------------	--------------------------------------	--------------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW
 APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH	5.5	4.7 - 7.5
SPECIFIC GRAVITY	<=1.005	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	2-3	0-5	/HPF
EPITHELIAL CELLS	3-5	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

REMARKS Please note that all the urinary findings are confirmed manually as well.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd (Formerly SRL Ltd)
 Gate No 2, Residency Area, Opp. St. Raphaels School,
 Indore, 452001
 Madhya Pradesh, India
 Tel : 0731 2490008

Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status **Final** **Results** **Biological Reference Interval** **Units**

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Arpita Pasari, MD
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3	124.60	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0	ng/dL
METHOD : CHEMILUMINESCENCE TECHNOLOGY			
T4	8.08	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
METHOD : CHEMILUMINESCENCE TECHNOLOGY			
TSH (ULTRASENSITIVE)	1.780	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL
METHOD : CHEMILUMINESCENCE TECHNOLOGY			

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
---------	-----	----------	-----	----------	---------------------



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 19 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684

PATIENT NAME : RITU SISODIA

REF. DOCTOR : DR. BANK OF BARODA

CODE/NAME & ADDRESS : C000138355

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0290WD003532

PATIENT ID : RITUF041081290

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 41 Years Female

DRAWN :

RECEIVED : 15/04/2023 08:41:25

REPORTED : 17/04/2023 16:36:44

Test Report Status **Final**

Results

Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062



Dr. Arpita Pasari, MD
Consultant Pathologist

Page 21 Of 21



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd (Formerly SRL Ltd)
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001
Madhya Pradesh, India
Tel : 0731 2490008



Patient Ref. No. 775000002914684